MARC record from Internet Archive

LEADER: 03100nam a22004094a 4500
001 2008940836
003 DLC
005 20100908174142.0
008 081103s2009 nyua b 001 0 eng c
010 $a 2008940836
015 $aGBA8B6716$2bnb
016 7 $a101502385$2DNLM
016 7 $a014771912$2Uk
020 $a9781588297372 (alk. paper)
020 $a1588297373 (alk. paper)
020 $a9781597453325 (e-ISBN)
020 $a1597453323 (e-ISBN)
035 $a(OCoLC)ocn261948167
040 $aNLM$cNLM$dUKM$dMMU$dPAU$dEMM$dDEBBG$dYDXCP$dBAKER$dDLC
042 $apcc
050 00 $aRC280.K5$bR466 2009
060 00 $a2009 D-966
060 10 $aWJ 358$bR39365 2009
084 $aXH 7850$2rvk
245 00 $aRenal cell carcinoma :$bmolecular targets and clinical applications /$cRonald M. Bukowski, Robert A. Figlin, Robert J. Motzer, editors.
250 $a2nd ed.
260 $aNew York :$bHumana Press,$cc2009.
300 $axvii, 507 p. :$bill. (some col.) ;$c24 cm.
504 $aIncludes bibliographical references and index.
505 0 $aTargeted therapy for metastatic renal call carcinoma: overview -- Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes -- Molecular targets in renal tumors: pathologic assessment -- Interferons and interleukin-2: molecular basis of activity and therapeutic results -- The molecular biology of kidney cancer and its clinical translation into treatment strategies -- VEGF: biologic aspects and clinical approaches -- VEGF and PDGF receptors: biologic relevance and clinical approaches to inhibition -- Sunitinib and axitinib in renal cell carcinoma -- Sorafenib in renal cell carcinoma -- Additional tyrosine kinase inhibitors in renal cell carcinoma -- Integrin [alpha]5[beta]1 as a novel therapeutic target in renal cancer -- Carbonic anhydrase IX: biology and clinical approaches -- Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies -- Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis -- P13K/Akt/mTOR pathway: a growth and proliferation pathway -- EGFR and HER2: relevance in renal cell carcinoma -- Proteasome-NF[kappa]B signaling pathway: relevance in RCC -- The role of hepatocyte growth factor pathway signaling in renal cell carcinoma -- Smac/DIABLO: a proapoptotic molecular target in renal cell cancer -- EphA2: a novel target in renal cell carcinoma -- Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma -- The role of gangliosides in renal cell carcinoma -- Tumour necrosis factor: misnomer and therapeutic target -- Molecular markers for predicting prognosis of renal cell carcinoma -- Adjuvant therapy for renal cell carcinoma: targeted approaches.
650 0 $aRenal cell carcinoma.
650 12 $aCarcinoma, Renal Cell.
650 22 $aKidney Neoplasms.
650 07 $aHypernephrom.$2swd
700 1 $aBukowski, Ronald M.
700 1 $aFiglin, Robert A.
700 1 $aMotzer, Robert J.